Abstract
This editorial discusses the current standstill in research in Parkinson’s disease from a clinician’s point of view [...]
Reference41 articles.
1. The three deceits of bureaucracy;Husain;Brain,2022
2. Freedman, L.P., Cockburn, I.M., and Simcoe, T.S. (2015). The Economics of Reproducibility in Preclinical Research. PLoS Biol., 13.
3. The impact of preclinical irreproducibility on drug development;Freedman;Clin. Pharmacol. Ther.,2015
4. What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?;Expert. Opin. Pharmacother.,2022
5. An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson’s disease;Tolosa;J. Neural Transm.,2018